Experienced in Scleroderma

Gerd-rudiger R. Burmester

Charité Universitätsmedizin
Berlin, BE, DE 
Experienced in Scleroderma
Charité Universitätsmedizin
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Gerd-rudiger Burmester practices in Berlin, Germany. Mr. Burmester is rated as an Experienced expert by MediFind in the treatment of Scleroderma. His top areas of expertise are Arthritis, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Reactive Arthritis, and Bone Marrow Transplant.

His clinical research consists of co-authoring 104 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Scleroderma.

Gender
Male

Locations

Charité Universitätsmedizin
Berlin, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

104 Total Publications

Associations between childhood trauma, depression, anxiety disorders and early arthritis presence.
Associations between childhood trauma, depression, anxiety disorders and early arthritis presence.
Journal: Frontiers in medicine
Published: February 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Burmester's expertise for a condition
ConditionClose
      View All 27 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile